BBP Virtus Biotech ETF
The Virtus Biotech ETF seeks to replicate the overall financial performance, encompassing both price appreciation and income generation, of the LifeSci Biotechnology Products Index, prior to any deductions for fees and expenses. This index specifically comprises biotechnology companies that have received approval from the FDA for at least one drug therapy. Furthermore, the fund underwent a name change on February 27, transitioning from Virtus LifeSci Biotech Products ETF to its current designation.
Performance
| 1M | 3M | YTD | 1Y | 3Y ann. | 5Y ann. | |
|---|---|---|---|---|---|---|
| BBP | +0.4% | -0.0% | +26.5% | +32.5% | +28.8% | +15.0% |
| Sector Equity average (81 funds) | -1.2% | -4.5% | +13.3% | +15.0% | +17.1% | +6.1% |
Insider activity in the holdings
Open-market insider buying across this fund’s holdings over 90 days, weighted by holding weight: +$301K net.
Holdings · as of Nov 13, 2026
| # | Holding | Weight |
|---|---|---|
| 1 | MRNA Moderna Inc | 6.41% |
| 2 | XERS Xeris Biopharma Holdings Inc | 3.13% |
| 3 | VSTM Verastem Inc | 2.85% |
| 4 | OMER Omeros Corp | 2.67% |
| 5 | IOVA Iovance Biotherapeutics Inc | 2.55% |
| 6 | KNSA Kiniksa Pharmaceuticals International Plc | 2.37% |
| 7 | ADMA ADMA Biologics Inc | 2.07% |
| 8 | BGNE BeOne Medicines Ltd | 2.04% |
| 9 | REGN Regeneron Pharmaceuticals Inc | 2.01% |
| 10 | ZLAB Zai Lab Ltd | 1.99% |
| 11 | HALO Halozyme Therapeutics Inc | 1.88% |
| 12 | ROIV Roivant Sciences Ltd | 1.79% |
| 13 | RIGL Rigel Pharmaceuticals Inc | 1.74% |
| 14 | GILD Gilead Sciences Inc | 1.74% |
| 15 | IRWD Ironwood Pharmaceuticals Inc | 1.72% |
| 16 | EXEL Exelixis Inc | 1.71% |
| 17 | TGTX TG Therapeutics Inc | 1.71% |
| 18 | AMGN Amgen Inc | 1.69% |
| 19 | ZYME Zymeworks Inc | 1.63% |
| 20 | RYTM Rhythm Pharmaceuticals Inc | 1.63% |
| 21 | BIIB Biogen Inc | 1.63% |
| 22 | LGND Ligand Pharmaceuticals Inc | 1.59% |
| 23 | TARS Tarsus Pharmaceuticals Inc | 1.59% |
| 24 | INSM Insmed Inc | 1.59% |
| 25 | VRTX Vertex Pharmaceuticals Inc | 1.58% |
| 26 | PTGX Protagonist Therapeutics Inc | 1.58% |
| 27 | BBIO Bridgebio Pharma Inc | 1.53% |
| 28 | ASND Ascendis Pharma A/S | 1.53% |
| 29 | ARQT Arcutis Biotherapeutics Inc | 1.50% |
| 30 | INCY Incyte Corp | 1.45% |
| 31 | NVAX Novavax Inc | 1.45% |
| 32 | AGIO Agios Pharmaceuticals Inc | 1.43% |
| 33 | IMCR Immunocore Holdings PLC | 1.41% |
| 34 | NBIX Neurocrine Biosciences Inc | 1.40% |
| 35 | UTHR United Therapeutics Corp | 1.40% |
| 36 | SRPT Sarepta Therapeutics Inc | 1.40% |
| 37 | PGEN Precigen Inc | 1.36% |
| 38 | BMRN BioMarin Pharmaceutical Inc | 1.34% |
| 39 | AUPH Aurinia Pharmaceuticals Inc | 1.32% |
| 40 | TVTX Travere Therapeutics Inc | 1.29% |
| 41 | HRMY Harmony Biosciences Holdings Inc | 1.28% |
| 42 | KRYS Krystal Biotech Inc | 1.25% |
| 43 | BNTX BioNTech SE | 1.24% |
| 44 | MIRM Mirum Pharmaceuticals Inc | 1.22% |
| 45 | IBRX ImmunityBio Inc | 1.21% |
| 46 | CRSP CRISPR Therapeutics AG | 1.18% |
| 47 | DNLI Denali Therapeutics Inc | 1.17% |
| 48 | MDGL Madrigal Pharmaceuticals Inc | 1.16% |
| 49 | GERN Geron Corp | 1.14% |
| 50 | BCRX BioCryst Pharmaceuticals Inc | 1.13% |
| 51 | NUVB Nuvation Bio Inc | 1.12% |
| 52 | ACAD ACADIA Pharmaceuticals Inc | 1.12% |
| 53 | PTCT PTC Therapeutics Inc | 1.11% |
| 54 | KURA Kura Oncology Inc | 1.10% |
| 55 | CYTK Cytokinetics Inc | 1.07% |
| 56 | LQDA Liquidia Corp | 1.00% |
| 57 | RARE Ultragenyx Pharmaceutical Inc | 0.88% |
| 58 | ARWR Arrowhead Pharmaceuticals Inc | 0.85% |
| 59 | PHAT Phathom Pharmaceuticals Inc | 0.78% |
| 60 | AXSM Axsome Therapeutics Inc | 0.75% |
| 61 | ALNY Alnylam Pharmaceuticals Inc | 0.73% |
| 62 | ARDX Ardelyx Inc | 0.71% |
| 63 | LEGN Legend Biotech Corp | 0.70% |
| 64 | SNDX Syndax Pharmaceuticals Inc | 0.68% |
| 65 | IONS Ionis Pharmaceuticals Inc | 0.50% |
| 66 | BBP Cash/Cash equivalents | 0.20% |
Sector breakdown
Country breakdown
Distributions
| Date | Per unit |
|---|---|
| Dec 20, 2017 | $0.0723 |
| Dec 21, 2015 | $0.3970 |
Members of Congress who disclosed this ETF
No member of Congress has disclosed a trade in BBP in the filings we hold.
Fund facts, prices, performance and distributions: our market-data vendor. Holdings: the vendor and SEC Form N-PORT. Insider and Congress data: InsiderBuying. Last updated Nov 13, 2026. This is historical data, not investment advice. Report a data error